Research programme: melanocortin analogues - Clinuvel Pharmaceuticals

Drug Profile

Research programme: melanocortin analogues - Clinuvel Pharmaceuticals

Alternative Names: CUV9900; VLRX 001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arizona
  • Class Hormones; Peptides; Skin disorder therapies
  • Mechanism of Action Melanocyte stimulating hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Vitiligo
  • No development reported Skin disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-disorders in Australia (Topical)
  • 05 May 2015 Preclinical trials in Vitiligo in Australia (Topical)
  • 19 Sep 2014 Preclinical development in Skin disorders is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top